pancuronium has been researched along with Chronic-Disease* in 3 studies
2 trial(s) available for pancuronium and Chronic-Disease
Article | Year |
---|---|
Randomised trial of routine versus selective paralysis during ventilation for neonatal respiratory distress syndrome.
The strategy of non-selective neuromuscular paralysis was compared with that of synchronised (fast rate) ventilation and selective paralysis in infants receiving mechanical ventilation for respiratory distress syndrome with chronic lung disease as the primary outcome measure. One hundred and ninety three infants weighing under 2000 g were randomly allocated to receive either pancuronium during mechanical ventilation in the acute phase of respiratory distress syndrome (non-selective group) or synchronised ventilation (initial ventilatory rate at or above that of the infant's) (selective group). Infants in the selective group received pancuronium if they were consistently expiring during the inspiratory phase of the ventilator cycle. There was no significant difference between the groups with respect to birth weight, gestation, and sex distribution. There was no significant difference between the group with respect to death (selective 19%, non-selective 16%), pneumothorax (selective 14%, non-selective 14%), chronic lung disease (selective 49%), non-selective 47%), and oxygen dependency at 36 weeks' postmenstrual age (selective 32%, non-selective 39%). Routine paralysis of ventilated infants has potential complications that may be avoided by using synchronised ventilation. As the latter is not associated with an increased incidence of long term respiratory complications, it is concluded that it is the optimum strategy of the two for ventilating infants with respiratory distress syndrome. Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lung Diseases; Male; Neuromuscular Junction; Pancuronium; Respiration, Artificial; Respiratory Distress Syndrome, Newborn; Treatment Outcome | 1993 |
Althesin and pancuronium in chronic liver disease.
In 32 patients with chronic liver disease, undergoing major abdominal surgery, anaesthesia was induced with either Althesin (alphaxalone and alphadolone acetate) or thiopentone, and maintained with nitrous oxide, oxygen and increments of either pethidine or fentanyl. The patients were ventilated artificially to maintain PaCO, values in the normal range. Pancuronium bromide was used as the muscle relaxant. Liver function tests at 24 hr and 5 day after surgery showed only minor changes compared with findings before operation. There was no significant difference between the Althesin and thiopentone groups. In two patients with severe obstructive jaundice there was difficulty in reversing the effects of pancuronium, but "pancuronium resistance" was observed in all patients. It is concluded that the anaesthetic sequence described, with either Althesin or thiopentone induction, is satisfactory with respect to changes in liver function in patients with chronic liver disease undergoing major surgery. Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Anesthesia, General; Chronic Disease; Humans; Liver Diseases; Liver Function Tests; Middle Aged; Nitrous Oxide; Pancuronium; Pregnanediones; Serum Albumin; Thiopental | 1975 |
1 other study(ies) available for pancuronium and Chronic-Disease
Article | Year |
---|---|
Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.
The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear. We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs. Two patients also received intravenous corticosteroids. Renal function was normal but hepatic function was impaired in all patients, and all had acidosis. Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations. Repetitive stimulation at 2 Hz showed a decremental response in 2 patients. The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments. The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids). Hepatic dysfunction and acidosis are contributing risk factors. Topics: Adrenal Cortex Hormones; Adult; Atracurium; Chronic Disease; Female; Humans; Male; Microscopy, Electron; Middle Aged; Muscles; Neuromuscular Nondepolarizing Agents; Pancuronium; Paralysis; Vecuronium Bromide | 1994 |